From the Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710
Calcium is a well established regulator of
transcription. Modulation of responses to this ubiquitous second
messenger can occur by superposition of coincident
Ca2+-independent signals, but there is also growing
evidence that the strength, frequency, source, and location of the
Ca2+ signal are determinants for specific transcriptional
results. These complex variations must be translated into changes in
protein function that preserve and process the information conveyed by the original signal. The Ca2+ receptor calmodulin
(CaM)1 is involved in many of
these changes through its effects on a variety of CaM-binding proteins
(1). Among these, the multifunctional Ca2+/calmodulin-dependent protein kinases
(CaMKs) are notable for their effects on components of transcription
complexes, directly connecting Ca2+ with changes in gene
expression. The highly homologous CaMKI and CaMKIV are distinct from
the multimeric CaMKII, although all have broad and overlapping
substrate preferences, because their activation is greatly enhanced
following phosphorylation catalyzed by "upstream" kinases in a
manner analogous to the mitogen-activated protein kinase
cascade. Based on an evolving understanding of CaMKI/IV regulation and
cloning of the CaMKI/IV kinases (CaMKKs), a
Ca2+/CaM-dependent protein kinase I/IV cascade
(CaMK cascade) has been proposed (2, 3). This review will discuss the
biochemical and physiologic basis for the existence of this cascade and
its potential for mediating Ca2+ regulation of transcription.
CaMKI and CaMKIV are closely related protein kinases with many
similarities in mode of activation and substrate preferences in
vitro but with different tissue distributions. The kinases are
regulated by Ca2+/CaM binding, which relieves
intramolecular steric inhibition of the active site by a C-terminal
autoinhibitory domain (Fig. 1). A second
autoinhibitory mechanism unique to CaMKIV is relaxed by the
autophosphorylation of Ser-12 and Ser-13 (4). In addition to
deinhibition, CaMKI and CaMIV are activated 10-50-fold by
trans phosphorylation on a single Thr residue in the
activation loop. Once activated, CaMKIV acquires Ca2+/CaM
independence, whereas CaMKI remains
Ca2+/CaM-dependent (5). Dephosphorylation and
inactivation of activated CaMKI/IV can be catalyzed in vitro
by PP1, PP2A, calcineurin (CaN), and the CaMK phosphatase, but the
relevant phosphatase(s) in vivo is still unclear (6,
7). CaMKI is ubiquitously expressed, whereas CaMKIV has a more limited
distribution, although both enzymes are strongly expressed in the
brain.
INTRODUCTION
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES
Identification and Biochemical Characterization of a CaMK
Cascade
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES
View larger version (24K):
[in a new window]
Fig. 1.
Stages of CaMKI/IV activation and effects on
activation-dependent (S) and
activation-independent (S') substrates. For
CaMKIV, autophosphorylation is also required in the first step but is
not depicted.
Recognition of the ability of kinases in brain extract to phosphorylate
and activate CaMKI/IV led to the cloning of two upstream kinases,
CaMKK and CaMKK
(8, 9). In addition to the brain, where both
CaMKKs are highly expressed, CaMKK
mRNA is found in thymus and
spleen, whereas CaMKK
is present at lower levels in all tissues that
express CaMKIV. Although derived from distinct genes, rat CaMKKs are
80% similar, and either CaMKK can phosphorylate and activate CaMKI and
CaMKIV in vitro. Both CaMKKs bind and are positively
regulated by Ca2+/CaM in vitro, and although
their CaM binding site is different from the other CaMKs, the
autoinhibitory mechanism functions in a similar manner to that of other
Ca2+/CaM-dependent kinases (10). Importantly,
Ca2+/CaM binding to CaMKI/IV is a prerequisite to
phosphorylation by the CaMKKs (5). Thus, in theory Ca2+/CaM
could regulate CaMKI/IV activity on many levels.
The substrate preferences of CaMKI and CaMKIV are similar and intersect with CaMKII. In vitro, all three can phosphorylate synapsin I, cAMP response element-binding protein (CREB), and activating transcription factor 1 (11, 12). Their minimum consensus sequence Hyd-X-R-X-X-(S/T) (where Hyd is any hydrophobic amino acid), determined through peptide studies, provides only a rough template common to many protein kinases (11). Additional specificity is provided by residues adjacent to the phosphorylation site of the substrate, producing differences in substrate preference among these kinases. The differences can have important transcriptional implications; for example, although all three can phosphorylate CREB on the activating site Ser-133, only CaMKII phosphorylates an additional inhibitory site, Ser-142 (13).
Interestingly, the presence of two additional basic amino acids 6 and 7 residues N-terminal to the phosphorylation site in certain peptide
substrates allows phosphorylation by CaMKI/IV equally well with or
without activation by a CaMKK (14). This "activation independence"
has not yet been demonstrated toward protein substrates. Nonetheless,
because CaMKI/IV requires Ca2+/CaM for deinhibition in
addition to activation loop phosphorylation, substrates of this type
would not be phosphorylated by CaMKI/IV until a Ca2+ signal
was initiated and so could represent
Ca2+-dependent but activation-independent
signaling targets. Subsequent activation by a CaMKK would increase the
number of available substrates by enhancing CaMKI/IV activity toward a
second set of substrates (Fig. 1).
![]() |
Does the Cascade Function in Cells? |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The first reconstruction of a CaMK cascade in cells used transient transfection experiments with CREB as the transcriptional target. CaMKI and CaMKIV phosphorylate CREB on its activating Ser-133 in vitro and stimulate Gal4-CREB-dependent transcription in response to a rise in intracellular Ca2+ when cells are cotransfected with Gal4-CREB and a Gal4 reporter gene (15). Additional cotransfection with a CaMKK increases reporter activity more than 10-fold (8, 9). Mutation of the CaMKIV activation loop T to A abolishes CaMKK enhancement.
To be a signaling cascade, kinase activation loop phosphorylation must be dependent upon induction of CaMKK activity. Phosphate incorporation into endogenous CaMKIV in Jurkat cells is induced rapidly following T-cell receptor stimulation and is blocked by chelation of extracellular Ca2+. This is accompanied by 8-14-fold increases in immunoprecipitated CaMKIV activity that is refractory to further activation by exogenous CaMKK and can be reversed by in vitro treatment with PP2A (16). Recombinant CaMKIV transfected into BJAB cells, which lack endogenous CaMKIV, demonstrates similar activation following anti-IgM stimulation that is abrogated by mutating the activation loop T to A (4). Likewise, CaMKI phosphorylation is induced in PC12 cells, coincident with increased CaMKI activity and reduced activation of CaMKI by exogenous CaMKK (17). Collectively, these experiments provide strong evidence for an inducible, Ca2+-dependent activation of CaMKI and CaMKIV in intact cells via activation loop phosphorylation. However, the fact that activation loop phosphorylation requires Ca2+ does not confirm that the physiologic activator is itself Ca2+-dependent, because Ca2+/CaM binding to CaMKI or CaMKIV is required before these enzymes can be phosphorylated by the known CaMKKs.
The issue of subcellular localization is a confounding one for any
model of the CaMK cascade regulating transcription. There are several
lines of evidence that CaMKK and -
are both cytoplasmic. In
contrast to an early study using a polyclonal antibody,
immunohistochemistry of rat brain slices using monoclonal antibodies
able to distinguish between the
and
isoforms found exclusively
cytoplasmic immunoreactivity for both (18). Furthermore, green
fluorescent protein-tagged CaMKK
and -
are cytoplasmic in NG108
cells even after depolarizing stimulation (18). This holds true for
overexpressed CaMKK
in Jurkat and BJAB
cells.2 Similarly, CaMKI
appears to be excluded from the nucleus in brain slices as well as in
cells overexpressing the protein, yet CaMKI immunoreactivity has
recently been observed to translocate to the nuclei of hippocampal
neurons during long term potentiation (19,
20).3 In contrast, CaMKIV is
predominantly nuclear but can also be found in neuronal soma and
dendritic processes, where it could interact with a cytoplasmic CaMKK
(21).
The CaMK cascade then is well positioned to affect cytoplasmic events, but it is more difficult to explain its effects on transcription. There could be changes in subcellular localization, an unidentified nuclear CaMKIV activator, or cytosolic CaMK cascade targets that modulate nuclear events. Whether full-length CaMKI enters the nucleus or affects transcription through a cytoplasmic intermediate has not been well studied, but it can stimulate transcription of reporters in transient transfection assays (15). Consequently, although the biochemistry is unambiguous and transient transfections appear to reconstruct a cascade, the mechanism for transcriptional regulation by a CaMK cascade in cells is more complicated than expected.
Several other pathways may influence or be influenced by the CaMK
cascade. CaMKI and protein kinase A can phosphorylate CaMKKs on
multiple inhibitory sites in vitro, and forskolin
stimulation reduces CaMKI/IV activation in several cell lines (22).
Likewise, nuclear localization of CaMKIIB and
B isoforms is inhibited by phosphorylation of their
nuclear localization sequence by CaMKI or CaMKIV, presumably
counteracting direct CaMKII effects on transcription (23). In addition,
in vitro experiments indicate CaMKK can phosphorylate and
activate both AMP kinase and protein kinase B, and the
AMP kinase kinase can phosphorylate and activate CaMKI, although
all of these effects are far less substantial than those of the
accepted activators AMP kinase kinase,
phosphoinositide-dependent kinase 1, and CaMKK, respectively (24-26).
Finally, Ras-independent activation of the mitogen-activated
protein kinases ERK2, p38, and JNK1 was observed in cells
transfected with constitutively active CaMKIV and further enhanced by
cotransfection with CaMKK
(27). The physiologic significance of
interacting signal cascades is still unclear, but these examples do
serve as a reminder of the intricacy of signal processing.
![]() |
Is the Cascade Physiologic? |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The evolutionary conservation of CaMKI/IV and CaMKK suggests a fundamental biological role. From Aspergillus nidulans to Caenorhabditis elegans to mammals, the cascade members are highly conserved and biochemically interchangeable in gross assays of cascade function in vitro (28, 29). Potential homologues have also been identified in Schizosaccharomyces pombe (30, 31) and Drosophila melanogaster (32). Investigating the CaMK cascade in genetically tractable systems will help determine whether it is a physiologic pathway and what biological functions it might regulate.
However, to assess the biological significance of the cascade, cellular
targets must be identified. CREB is a likely possibility, as it can be
activated by the CaMK cascade in transfection experiments (Fig.
2), but many kinases can be induced to
phosphorylate CREB (33, 34). It seems likely that the physiologic
kinase(s) depends on the situation. For example, expression of
catalytically inactive, dominant negative CaMKIV (dnCaMKIV)
specifically in developing thymocytes blocks CREB phosphorylation on
Ser-133, leading to effects including decreased interleukin-2
production that are reminiscent of thymocytes from mice expressing
dnCREB S133A (35). Yet, in initial experiments with thymocytes from
CaMKIV-null mice, Ser-133 phosphorylation is subtly decreased but not
prevented, and total interleukin-2 production appears
normal.4 The most
parsimonious explanation for these conflicting observations is that the
dnCaMKIV prevented CREB phosphorylation not only by CaMKIV but also by
other thymic CREB kinases. In contrast, CREB phosphorylation is
severely reduced in both cerebellar extracts and stimulated hippocampal
neurons of CaMKIV knockout mice but is unaffected in the testis
(36-38). These results suggest that CaMKIV functions as a CREB kinase
in some but not all tissues. Evaluation of CREB phosphorylation in the
absence of CaMKKs awaits development of appropriate genetic models.
|
Situation-specific signal regulation could be accomplished, in part,
through regulated association of CaMKIV with other cellular components.
An avid association between CaMKIV and PP2A has been demonstrated by
copurification and coprecipitation; immunoprecipitated CaMKIV is nearly
stoichiometrically associated with PP2A, although the reverse is not
true because of the large excess of PP2A (39). Inhibition of PP2A with
adenovirus small t antigen or okadaic acid increases
CaMKIV-dependent activation of Gal4-CREB transcription, which could result from blocking dephosphorylation of CaMKIV, CREB,
and/or CBP. In contrast to the apparently constitutive association of
CaMKIV with a potential deactivator, attempts to coprecipitate CaMKIV
and CaMKK have been unsuccessful, suggesting that the preformed signaling complex may not include the known activators.2
Although its significance is not understood, biochemical fractionation of testis extract indicates that a hyperphosphorylated form of CaMKIV
is associated with the nuclear matrix (40). Targeting CaMKIV to
appropriate loci in a preformed signaling complex could be an important
factor in its effects on transcription. As the example of CREB
phosphorylation in CaMKIV-null mice poignantly demonstrates, we cannot
yet predict when a transcription factor that can be regulated by CaMKIV
in transfected cells will be regulated by CaMKIV in vivo and
how that specificity is determined.
![]() |
Other Transcriptional Targets of CaMKIV |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
CaMKIV has been linked with the regulation of many transcription factors other than CREB, including AP-1, serum response factor, and activating transcription factor 1, and may have multiple modes of regulating CREB-dependent transcription (Fig. 2) (12). CREB transcriptional activation occurs through its binding to the coactivator protein CBP/p300, which links many transcription factors to components of the general transcriptional machinery. Phosphorylation of CREB on Ser-133 increases its affinity for CBP but whether CREB Ser-133 phosphorylation is sufficient to induce CRE-dependent transcription without other regulatory signals to CBP itself is controversial. Microinjection of phosphoserine 133-CREB or transfection with the Y134F CREB mutant that is constitutively phosphorylated induces CRE-dependent reporter plasmid transcription without additional stimuli (41, 42). Seemingly contradictory experiments demonstrate that induction of CRE-mediated transcription by depolarization of AtT20 cells requires nuclear Ca2+ but not increased CREB Ser-133 phosphorylation (43). Moreover, reporter gene transcription driven by a CREB-independent Gal4-CBP fusion is enhanced by constitutively active CaMKIV. Sites in CBP are inducibly phosphorylated, which has led to the hypothesis that CaMKIV regulates CBP by direct phosphorylation, but this remains to be demonstrated.
CaMKIV stimulation of transcription by the orphan receptor ROR may
also be related to effects on coactivators. A CaMKIV effect on ROR was
investigated because of the similarities in phenotypes between CaMKIV
and ROR
knockout mice. In transfection assays, CaMKIV induces a
20-30-fold increase in ROR
-dependent transcription of a
reporter plasmid (44). The ROR
ligand binding domain (LBD) is not a
substrate for CaMKIV in vitro, but LBD binding peptides that
disrupt LBD association with endogenous coactivators abrogate the
CaMKIV effect. Although the mechanism remains to be elucidated, these
results and the CaMKIV effects on CBP suggest a new role for CaMKIV in
recruiting or stabilizing coactivator-containing transcriptional complexes.
CaMKIV has also been implicated in the
Ca2+-dependent regulation of MEF2 family
transcription factors (Fig. 3). In
cardiomyocytes and neurons, Ca2+ influx leading to MEF2
activation correlates with activation of p38, which phosphorylates MEF2
on multiple sites in vitro including those in its activation
domain (45, 46). MEF2 has also been reported to be a substrate for
CaMKIV in vitro (47). Constitutive forms of CaMKI/IV and CaN
independently activate MEF2 reporter genes but synergize when
cotransfected. There is evidence for two complementary mechanisms for
the effect of CaN: dephosphorylation of NFAT, promoting its nuclear
translocation and allowing it to synergize with MEF2 to activate
reporter genes; and dephosphorylation of MEF2, which enhances its DNA
binding (48). The coactivator CBP/p300 can bind both NFAT and MEF2 and
may be involved in stabilizing a NFAT-MEF2 complex on the promoter
and/or may itself be a target of a
Ca2+-dependent stimulatory signal (49).
Furthermore, Cabin-1, originally identified as a CaN inhibitor,
also binds and suppresses MEF2 transcriptional activity in T-cells
(50). Cabin-1 binding to MEF2 is competitive with p300 and is relieved
by Ca2+/CaM binding to Cabin-1 (50, 51). Because
Cabin-1 also associates with mSin3a and histone deacetylases 1 and 2 (HDAC1/2), its dissociation from MEF2 may replace a repressing complex
with an activating complex (51). In a like manner, MEF2 binds and is
repressed by HDAC4 but is released by Ca2+/CaM binding to
HDAC4 (52). Association of MEF2 with HDAC4/5 can also be inhibited by
cotransfection with a constitutively active fragment of CaMKI/IV, which
may provide an indirect mechanism for CaMKI/IV enhancement of MEF2
transcription (53). Clearly, Ca2+ regulation of MEF2 is
multifaceted, involving both stimulatory phosphorylation/dephosphorylation and dissociation from transcriptional repressors.
|
Missing from many studies of CaMKIV and transcription is a
characterization of CaMKK effects and differentiation between CaMKI and
CaMKIV. Unfortunately, the kinase inhibitors currently available, KN62
and KN93, inhibit CaMKI, II, and IV similarly and so they cannot be
used alone to define a role for a specific CaMK (54). Moreover, these
drugs block voltage-dependent K+ currents at
concentrations comparable with those used for CaMK inhibition, so
results from the use of these inhibitors should be interpreted
cautiously (55). Truncations of the kinases to form constitutively
active forms are also frequently used to study transcription, but
because this removes domains of the kinase whose functions are unknown,
these proteins could be inappropriately localized or regulated. For
example, the CaMKII-(1-290) activating truncation also removes the
association domain and thus both changes its activation biochemistry
and permits inappropriate nuclear entry (2, 11). For CaMKI and CaMKIV,
functions of the C-terminal region are not as well defined but may also
affect subcellular distribution and substrate preference. One
alternative approach that circumvents these pitfalls but has not yet
been extensively employed is to use mutations in the autoinhibitory
domains identified for CaMKII, CaMKIV, and CaMKKs that allow
Ca2+/CaM-independent activity without truncation (10, 56,
57). Finally, because understanding of the cascade is still so
skeletal, it is not reasonable to assume that transcriptional effects
attributed to CaMKIV are also regulated by the CaMKK without directly
testing that hypothesis. These caveats should be kept in mind in
interpreting the results of experiments designed to implicate one of
the CaMKs in a CaMK cascade.
![]() |
Evidence for a CaMK Cascade |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The evidence for a working CaMK cascade regulating Ca2+-dependent transcription in cells is largely favorable but still circumstantial. CaMKI and CaMKIV are excellent substrates of the CaMKKs and are dramatically activated by activation loop phosphorylation that occurs following stimulation of intact cells. The tissue distributions of the CaMKKs appropriately overlap those of CaMKI and CaMKIV, but the question of subcellular localization still needs to be resolved. Whether the CaMKKs so far identified are the only kinases capable of activating CaMKI and CaMKIV is unknown.
If this cascade is physiologic, does it function as a signal integrator
or as an amplification circuit? Of course, inducible phosphorylation by
CaMKKs provides a mechanism for amplification. However, like CaMKII,
these kinases have elaborate activation mechanisms that rely on a
Ca2+ signal for multiple steps. For CaMKII, this complex
activation biochemistry has been shown to differentiate stimulation
frequencies (58), but no such evidence yet exists for the CaMK cascade. The suggestion from peptide experiments that CaMKI/IV might exhibit different substrate specificities before and after activation offers
tantalizing possibilities for signal processing beyond amplification.
Elements of the cascade also interact with a variety of other pathways,
and the CaMKKs may have substrates other than CaMKI/IV. Therefore, both
amplification and integration are possible roles for a CaMK cascade.
The intricate regulation of these kinases provides many interesting
possibilities for transmitting Ca2+ signals.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank K. E. Winkler, J. D. Joseph, C. D. Kane, K. A. Anderson, and I. R. Asplin for helpful discussions and critical reading of the manuscript, and S. S. Hook and K. A. Anderson for permission to discuss unpublished data.
![]() |
FOOTNOTES |
---|
* This minireview will be reprinted in the 2001 Minireview Compendium, which will be available in December, 2001. This is the second article of four in the "Ca2+-dependent Cell Signaling through Calmodulin-activated Protein Phosphatase and Protein Kinases Minireview Series." Our research was supported by United States Army Grant DAMD17-97-1-7331(to E. E. C.) and National Institutes of Health Grants HD07503 and GM33976 (to A. R. M.).
To whom correspondence should be addressed: Dept. of Pharmacology
and Cancer Biology, Duke University Medical Center, Box 3813, Durham,
NC 27710. Tel.: 919-681-6209; Fax: 919-681-7767; E-mail:
means001@mc.duke.edu.
Published, JBC Papers in Press, November 28, 2000, DOI 10.1074/jbc.R000027200
2 E. E. Corcoran and A. R. Means, unpublished data.
3 S. S. Hook and A. R. Means, unpublished data.
4 K. A. Anderson and A. R. Means, unpublished data.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: CaM, calmodulin; CaMK, Ca2+/calmodulin-dependent protein kinase; CaMKK, CaMKI/IV kinase; CaN, calcineurin; CREB, cAMP response element-binding protein; CBP, CREB-binding protein; CRE, cAMP response element; dn, dominant negative; ROR, retinoic acid-related orphan receptor; LBD, ligand binding domain.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Chin, D., and Means, A. R. (2000) Trends Cell Biol. 10, 322-328[CrossRef][Medline] [Order article via Infotrieve] |
2. |
Means, A. R.
(2000)
Mol. Endocrinol.
14,
4-13 |
3. | Soderling, T. R. (1999) Trends Biochem. Sci. 24, 232-236[CrossRef][Medline] [Order article via Infotrieve] |
4. |
Chatila, T.,
Anderson, K. A.,
Ho, N.,
and Means, A. R.
(1996)
J. Biol. Chem.
271,
21542-21548 |
5. | Haribabu, B., Hook, S. S., Selbert, M. A., Goldstein, E. G., Tomhave, E. D., Edelman, A. M., Snyderman, R., and Means, A. R. (1995) EMBO J. 14, 3679-3686[Abstract] |
6. |
Kasahara, J.,
Fukunaga, K.,
and Miyamoto, E.
(1999)
J. Biol. Chem.
274,
9061-9067 |
7. | Kitani, T., Ishida, A., Okuno, S., Takeuchi, M., Kameshita, I., and Fujisawa, H. (1999) J. Biochem. (Tokyo) 125, 1022-1028[Abstract] |
8. |
Tokumitsu, H.,
Enslen, H.,
and Soderling, T. R.
(1995)
J. Biol. Chem.
270,
19320-19324 |
9. |
Anderson, K. A.,
Means, R. L.,
Huang, Q. H.,
Kemp, B. E.,
Goldstein, E. G.,
Selbert, M. A.,
Edelman, A. M.,
Fremeau, R. T.,
and Means, A. R.
(1998)
J. Biol. Chem.
273,
31880-31889 |
10. |
Tokumitsu, H.,
Muramatsu, M.,
Ikura, M.,
and Kobayashi, R.
(2000)
J. Biol. Chem.
275,
20090-20095 |
11. | Schulman, H., and Braun, A. (1999) in Calcium as a Cellular Regulator (Carafoli, E. , and Klee, C., eds) , pp. 311-343, Oxford University Press, New York |
12. | Anderson, K. A., and Kane, C. D. (1998) Biometals 11, 331-343[CrossRef][Medline] [Order article via Infotrieve] |
13. | Sun, P., Enslen, H., Myung, P. S., and Maurer, R. A. (1994) Genes Dev. 8, 2527-2539[Abstract] |
14. |
Hook, S. S.,
Kemp, B. E.,
and Means, A. R.
(1999)
J. Biol. Chem.
274,
20215-20222 |
15. |
Sun, P.,
Lou, L.,
and Maurer, R. A.
(1996)
J. Biol. Chem.
271,
3066-3073 |
16. |
Park, I. K.,
and Soderling, T. R.
(1995)
J. Biol. Chem.
270,
30464-30469 |
17. |
Aletta, J. M.,
Selbert, M. A.,
Nairn, A. C.,
and Edelman, A. M.
(1996)
J. Biol. Chem.
271,
20930-20934 |
18. | Sakagami, H., Umemiya, M., Saito, S., and Kondo, H. (2000) Eur. J. Neurosci. 12, 89-99[CrossRef][Medline] [Order article via Infotrieve] |
19. | Picciotto, M. R., Zoli, M., Bertuzzi, G., and Nairn, A. C. (1995) Synapse 20, 75-84[Medline] [Order article via Infotrieve] |
20. | Ahmed, B. Y., Yamaguchi, F., Tsumura, T., Gotoh, T., Sugimoto, K., Tai, Y., Konishi, R., Kobayashi, R., and Tokuda, M. (2000) Neurosci. Lett. 290, 149-153[CrossRef][Medline] [Order article via Infotrieve] |
21. | Nakamura, Y., Okuno, S., Sato, F., and Fujisawa, H. (1995) Neuroscience 68, 181-194[CrossRef][Medline] [Order article via Infotrieve] |
22. |
Matsushita, M.,
and Nairn, A. C.
(1999)
J. Biol. Chem.
274,
10086-10093 |
23. |
Heist, E. K.,
Srinivasan, M.,
and Schulman, H.
(1998)
J. Biol. Chem.
273,
19763-19771 |
24. |
Hawley, S. A.,
Selbert, M. A.,
Goldstein, E. G.,
Edelman, A. M.,
Carling, D.,
and Hardie, D. G.
(1995)
J. Biol. Chem.
270,
27186-27191 |
25. | Yano, S., Tokumitsu, H., and Soderling, T. R. (1998) Nature 396, 584-587[CrossRef][Medline] [Order article via Infotrieve] |
26. | Okuno, S., Kitani, T., Matsuzaki, H., Konishi, H., Kikkawa, U., and Fujisawa, H. (2000) J. Biochem. (Tokyo) 127, 965-970[Abstract] |
27. |
Enslen, H.,
Tokumitsu, H.,
Stork, P. J.,
Davis, R. J.,
and Soderling, T. R.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10803-10808 |
28. |
Eto, K.,
Takahashi, N.,
Kimura, Y.,
Masuho, Y.,
Arai, K.,
Muramatsu, M. A.,
and Tokumitsu, H.
(1999)
J. Biol. Chem.
274,
22556-22562 |
29. |
Joseph, J. D.,
and Means, A. R.
(2000)
J. Biol. Chem.
275,
38230-38238 |
30. |
Rasmussen, C. D.
(2000)
J. Biol. Chem.
275,
685-690 |
31. |
Rupes, I.,
Jia, Z.,
and Young, P. G.
(1999)
Mol. Biol. Cell
10,
1495-1510 |
32. |
Xu, X. Z.,
Wes, P. D.,
Chen, H.,
Li, H. S., Yu, M.,
Morgan, S.,
Liu, Y.,
and Montell, C.
(1998)
J. Biol. Chem.
273,
31297-31307 |
33. | Shaywitz, A. J., and Greenberg, M. E. (1999) Annu. Rev. Biochem. 68, 821-861[CrossRef][Medline] [Order article via Infotrieve] |
34. | Bito, H., Deisseroth, K., and Tsien, R. W. (1997) Curr. Opin. Neurobiol. 7, 419-429[CrossRef][Medline] [Order article via Infotrieve] |
35. |
Anderson, K. A.,
Ribar, T. J.,
Illario, M.,
and Means, A. R.
(1997)
Mol. Endocrinol.
11,
725-737 |
36. | Wu, J. Y., Ribar, T. J., Cummings, D. E., Burton, K. A., McKnight, G. S., and Means, A. R. (2000) Nat. Genet. 25, 448-452[CrossRef][Medline] [Order article via Infotrieve] |
37. |
Ho, N.,
Liauw, J. A.,
Blaeser, F.,
Wei, F.,
Hanissian, S.,
Muglia, L. M.,
Wozniak, D. F.,
Nardi, A.,
Arvin, K. L.,
Holtzman, D. M.,
Linden, D. J.,
Zhuo, M.,
Muglia, L. J.,
and Chatila, T. A.
(2000)
J. Neurosci.
20,
6459-6472 |
38. |
Ribar, T. J.,
Rodriguiz, R. M.,
Khiroug, L.,
Wetsel, W. C.,
Augustine, G. J.,
and Means, A. R.
(2000)
J. Neurosci.
20,
1-5 |
39. |
Westphal, R. S.,
Anderson, K. A.,
Means, A. R.,
and Wadzinski, B. E.
(1998)
Science
280,
1258-1261 |
40. |
Wu, J. Y.,
and Means, A. R.
(2000)
J. Biol. Chem.
275,
7994-7999 |
41. |
Alberts, A. S.,
Arias, J.,
Hagiwara, M.,
Montminy, M. R.,
and Feramisco, J. R.
(1994)
J. Biol. Chem.
269,
7623-7630 |
42. |
Du, K.,
Asahara, H.,
Jhala, U. S.,
Wagner, B. L.,
and Montminy, M.
(2000)
Mol. Cell. Biol.
20,
4320-4327 |
43. |
Chawla, S.,
Hardingham, G. E.,
Quinn, D. R.,
and Bading, H.
(1998)
Science
281,
1505-1509 |
44. |
Kane, C. D.,
and Means, A. R.
(2000)
EMBO J.
19,
691-701 |
45. |
Mao, Z.,
Bonni, A.,
Xia, F.,
Nadal-Vicens, M.,
and Greenberg, M. E.
(1999)
Science
286,
785-790 |
46. |
Zhao, M.,
New, L.,
Kravchenko, V. V.,
Kato, Y.,
Gram, H.,
di Padova, F.,
Olson, E. N.,
Ulevitch, R. J.,
and Han, J.
(1999)
Mol. Cell. Biol.
19,
21-30 |
47. |
Blaeser, F.,
Ho, N.,
Prywes, R.,
and Chatila, T. A.
(2000)
J. Biol. Chem.
275,
197-209 |
48. | Olson, E. N., and Williams, R. S. (2000) Bioessays 22, 510-519[CrossRef][Medline] [Order article via Infotrieve] |
49. |
Youn, H. D.,
Chatila, T. A.,
and Liu, J. O.
(2000)
EMBO J.
19,
4323-4331 |
50. |
Youn, H. D.,
Sun, L.,
Prywes, R.,
and Liu, J. O.
(1999)
Science
286,
790-793 |
51. | Youn, H. D., and Liu, J. O. (2000) Immunity 13, 85-94[Medline] [Order article via Infotrieve] |
52. |
Youn, H. D.,
Grozinger, C. M.,
and Liu, J. O.
(2000)
J. Biol. Chem.
275,
22563-22567 |
53. |
Lu, J.,
McKinsey, T. A.,
Nicol, R. L.,
and Olson, E. N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
4070-4075 |
54. | Hidaka, H., and Yokokura, H. (1996) Adv. Pharmacol. 36, 193-219[Medline] [Order article via Infotrieve] |
55. |
Ledoux, J.,
Chartier, D.,
and Leblanc, N.
(1999)
J. Pharmacol. Exp. Ther.
290,
1165-1174 |
56. |
Mukherji, S.,
Brickey, D. A.,
and Soderling, T. R.
(1994)
J. Biol. Chem.
269,
20733-20738 |
57. |
Tokumitsu, H.,
Brickey, D. A.,
Glod, J.,
Hidaka, H.,
Sikela, J.,
and Soderling, T. R.
(1994)
J. Biol. Chem.
269,
28640-28647 |
58. |
De Koninck, P.,
and Schulman, H.
(1998)
Science
279,
227-230 |